drugset
drugset / Trial / NCT02199197

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

NCT02199197 ↗

Phase 2 Completed 49 enrolled University of Utah
RandomizedParallel-groupOpen-labelTreatment

Summary

Study of Radium Ra 223 dichloride with enzalutamide compared to enzalutamide alone in men with metastatic castration refractory prostate cancer

Timeline

Start
2014-06-25
Primary completion
2018-04-19
Completion
2019-10-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 160 mg Oral
Subject Radium-223 dichloride Other / unclassified 55 mbq/kg Intravenous

Indications

prostate cancer